Lenexa, KS – In their ongoing effort to offer "Ingredients with a Difference" to dietary supplement manufacturers, Wilke Resources has entered into an agreement with Next Pharmaceuticals, Inc., Irvine, CA to act as the exclusive USA sales agent for Next’s flagship products, Relora® and Nexrutine®. Relora® is the branded, patent-pending plant extract blend from Magnolia officinalis and Phellodendron amurense that delilvers natural stress management and stress-related appetite control. Its sister product, Nexrutine®, is a patent-pending branded extract of Phellodendron amurense that serves as a natural COX-2 inhibitor and helps support normal, healthy, pain-free muscle recovery and joint flexibility after exercise.
Relora® and Nexrutine® are both compatible and synergistic with WRI’s existing weight loss (LipoSan Ultra™ from Vanson HaloSource) and joint support products (Glucosamine and Chondroitin Sulfate). According to Jim France, General Manager Wilke Resources, "The addition of Relora® and Nexrutine® to our product line will permit us to expand our ability to supply efficacious, science-backed products in two key application areas, stress-related weight loss and natural pain relief." WRI's other cutting edge ingredients include ImmunoLin™ for concentrated immune system support and gut health, D-Mannose for urinary tract support, and VitaHeme™ heme iron supplement for kinder, gentler iron supplementation.
For more information on Relora® and Nexrutine®, please feel free to visit our website (http://www.wilkeresources.com) or contact Jim France, Jim Maguire or Kristine Haigh by phone (800-779-5545) or e-mail ([email protected]).
- Relora® and Nexrutine® are registered trademarks of Next Pharmaceuticals, Inc.
- LipoSan Ultra™ is a trademark of Vanson Halosource Inc.
- ImmunoLin™ and VitaHeme™ are trademarks of Proliant Inc.